罗欣药业(002793) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥1,275,320,618.09, a decrease of 29.21% compared to ¥1,801,618,651.10 in the same period last year[8] - The net profit attributable to shareholders was ¥111,611,818.85, down 10.97% from ¥125,370,315.98 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥98,907,054.75, representing a decline of 19.43% compared to ¥122,763,757.85 in the previous year[8] - Basic earnings per share decreased by 33.33% to ¥0.08 from ¥0.12 year-on-year[8] - The company's operating profit for Q1 2020 was approximately ¥133.44 million, a decrease of 13.3% compared to ¥153.86 million in Q1 2019[43] - The total comprehensive income for Q1 2020 was approximately ¥114.99 million, a decline of 18.7% from ¥141.48 million in Q1 2019[44] - The company's revenue from sales of goods and services in Q1 2020 was approximately ¥1.23 billion, down from ¥1.51 billion in Q1 2019[50] - The company's total profit for Q1 2020 was approximately ¥133.17 million, a decrease of 13.0% from ¥152.89 million in Q1 2019[43] Cash Flow and Liquidity - The net cash flow from operating activities improved to -¥172,069,444.30, a 66.87% increase from -¥519,396,823.04 in the same period last year[8] - The company reported a significant increase in cash and cash equivalents, reaching ¥1,617,221,336.82 as of March 31, 2020, up 45.89% from ¥1,108,522,589.29 on December 31, 2019[18] - The total cash and cash equivalents at the end of the period reached 1,223,703,360.29 yuan, an increase of 21.5% from 1,007,325,634.24 yuan[52] - The company reported a net increase in cash and cash equivalents of 397,764,471.67 yuan, compared to 170,976,325.61 yuan in the previous period, reflecting a growth of approximately 133.2%[52] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,571,134,832.67, an increase of 1.48% from ¥7,460,560,292.68 at the end of the previous year[8] - The net assets attributable to shareholders increased by 4.79% to ¥3,855,139,324.66 from ¥3,679,078,811.36 at the end of the previous year[8] - Total liabilities decreased to CNY 3,434,861,168.62 from CNY 3,498,805,588.74, reflecting a reduction in financial obligations[36] - Total liabilities amounted to CNY 3,498,805,588.74, with current liabilities at CNY 2,950,916,283.65 and non-current liabilities at CNY 547,889,305.09[59] - The total assets of the company were reported at CNY 7,460,560,292.68, with current assets totaling CNY 248,294,851.07 and non-current assets at CNY 7,538,910,000.00[59] Expenses - Sales expenses decreased by 49.42% year-over-year to ¥386,648,861.39 in Q1 2020, primarily due to reduced promotional costs amid the pandemic[18] - The company’s financial expenses surged by 199.34% to ¥16,508,777.11 in Q1 2020, attributed to increased borrowing[18] - Research and development expenses for Q1 2020 were CNY 96,748,171.03, compared to CNY 111,625,441.17 in the previous period, indicating a reduction in investment in innovation[42] - The income tax expense for Q1 2020 was approximately ¥22.72 million, an increase of 35.5% from ¥16.77 million in Q1 2019[43] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,958[13] - The company issued a total of 1,075,471,621 new shares as part of the asset acquisition, increasing total shares outstanding to 1,445,991,217[19] - Total equity attributable to shareholders rose to CNY 3,855,139,324.66 from CNY 3,679,078,811.36, showing growth in shareholder value[36] Other Information - The company completed a major asset restructuring, acquiring 99.65476% of Shandong Luoxin, transitioning its main business to pharmaceutical manufacturing[19] - The company has not undergone an audit for the first quarter report, indicating that the figures are unaudited[62] - The company has implemented new revenue and leasing standards starting in 2020, but this does not apply to the current report[62]